<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Ther Oncolytics</journal-id><journal-id journal-id-type="iso-abbrev">Mol Ther Oncolytics</journal-id><journal-title-group><journal-title>Molecular Therapy Oncolytics</journal-title></journal-title-group><issn pub-type="epub">2372-7705</issn><publisher><publisher-name>American Society of Gene &#x00026; Cell Therapy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28607949</article-id><article-id pub-id-type="pmc">5458115</article-id><article-id pub-id-type="publisher-id">S2372-7705(17)30022-0</article-id><article-id pub-id-type="doi">10.1016/j.omto.2017.05.003</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Non-glycanated Decorin Is a Drug Target on Human Adipose Stromal Cells</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Daquinag</surname><given-names>Alexes C.</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Dadbin</surname><given-names>Ali</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Snyder</surname><given-names>Brad</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Xiaoping</given-names></name><xref rid="aff3" ref-type="aff">3</xref><xref rid="aff4" ref-type="aff">4</xref><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Sahin</surname><given-names>Aysegul A.</given-names></name><xref rid="aff6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name><surname>Ueno</surname><given-names>Naoto T.</given-names></name><xref rid="aff3" ref-type="aff">3</xref><xref rid="aff4" ref-type="aff">4</xref><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Kolonin</surname><given-names>Mikhail G.</given-names></name><email>mikhail.g.kolonin@uth.tmc.edu</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib></contrib-group><aff id="aff1"><label>1</label>The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX 77030, USA</aff><aff id="aff2"><label>2</label>Department of Surgery, University of Texas Health Science Center at Houston, Houston, TX 77030, USA</aff><aff id="aff3"><label>3</label>Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA</aff><aff id="aff4"><label>4</label>Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA</aff><aff id="aff5"><label>5</label>Section of Translational Breast Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA</aff><aff id="aff6"><label>6</label>Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA</aff><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author: Mikhail G. Kolonin, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, 1825 Pressler Street, Room 630-G, Houston, TX 77030, USA. <email>mikhail.g.kolonin@uth.tmc.edu</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>17</day><month>5</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><day>15</day><month>9</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>17</day><month>5</month><year>2017</year></pub-date><volume>6</volume><fpage>1</fpage><lpage>9</lpage><history><date date-type="received"><day>27</day><month>1</month><year>2017</year></date><date date-type="accepted"><day>10</day><month>5</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 The Authors</copyright-statement><copyright-year>2017</copyright-year><license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract id="abs0010"><p>Adipose stromal cells (ASCs) have been identified as a mesenchymal cell population recruited from white adipose tissue (WAT) by tumors and supporting cancer progression. We have previously reported the existence of a non-glycanated decorin isoform (ngDCN) marking mouse ASCs. We identified a peptide CSWKYWFGEC that binds to ngDCN and hence can&#x000a0;serve as a vehicle for ASC-directed therapy delivery. We used hunter-killer peptides composed of CSWKYWFGEC and a&#x000a0;pro-apoptotic moiety to deplete ASCs and suppress growth&#x000a0;of mouse tumors. Here, we report the discovery of the&#x000a0;human non-glycanated decorin isoform. We show that CSWKYWFGEC can be used as a probe to identify ASCs in human WAT and tumors. We demonstrate that human ngDCN is expressed on ASC surface. Finally, we validate ngDCN as a molecular target for pharmacological depletion of human ASCs with hunter-killer peptides. We propose that ngDCN-targeting agents could be developed for obesity and cancer treatment.</p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>adipose stromal cell</kwd><kwd>peptide</kwd><kwd>decorin</kwd></kwd-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p>There is an urgent need to identify novel anti-cancer druggable targets and therapies. Our previous studies have elucidated the role of tumor stromal cells derived from white adipose tissue (WAT), which contains large numbers of adipose stromal cells (ASCs), the mesenchymal stromal cell (MSC) population expanded in obesity.<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref> We have shown that WAT contributes to the pool of tumor stromal cells<xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref> in both mice<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> and patients.<xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref> There is accumulating evidence that WAT surrounding the tumor is a key source of tumor stroma and that adenocarcinoma growth and progression is associated with infiltration of ASCs derived from WAT. Our recent study has identified ASCs recruitment by tumors as the mechanism through which WAT promotes cancer progression and link ASCs recruitment with poor patient survival.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> In animal studies, administered ASCs engraft tumors, which results in accelerated cancer progression.<xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref> Our findings confirmed by data from other groups<xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib11" ref-type="bibr">11</xref>, <xref rid="bib12" ref-type="bibr">12</xref>, <xref rid="bib13" ref-type="bibr">13</xref>, <xref rid="bib14" ref-type="bibr">14</xref> demonstrate tumor recruitment of endogenous ASCs and indicate that ASCs promote survival and proliferation of neighboring malignant cells. The apparent contribution of ASCs to the tumor microenvironment has raised a question regarding the safety of lipotransfer procedures in cancer patients.<xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib16" ref-type="bibr">16</xref>, <xref rid="bib17" ref-type="bibr">17</xref> There is also emerging evidence that ASCs contribute to therapy resistance of various cancers.<xref rid="bib18" ref-type="bibr">18</xref>, <xref rid="bib19" ref-type="bibr">19</xref></p><p>We and others have discovered that ASCs can be identified as cells positive for mesenchymal markers and CD34 while negative for endothelial (CD31) and hematopoietic (CD45) markers.<xref rid="bib20" ref-type="bibr">20</xref>, <xref rid="bib21" ref-type="bibr">21</xref> We had originally reported platelet-derived growth factor receptor-alpha (PDGFR&#x003b1;) and PDGFR-beta (PDGFR&#x003b2;), also known as CD140a and CD140b, as mesenchymal markers expressed on human ASCs.<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> Subsequently, PDGFR&#x003b1; and PDGFR&#x003b2; have been validated as adipocyte progenitors in mice by lineage tracing.<xref rid="bib22" ref-type="bibr">22</xref>, <xref rid="bib23" ref-type="bibr">23</xref>, <xref rid="bib24" ref-type="bibr">24</xref> We have shown that stromal cells expressing either PDGFR&#x003b1; or PDGFR&#x003b2; are recruited by tumors in mouse models.<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> However, both PDGFR&#x003b1; and PDGFR&#x003b2;, as well as other mesenchymal markers, are expressed on various cell populations in different organs. Therefore, they cannot serve as specific markers of ASCs, and the lack of molecules expressed on ASCs, but not on other MSCs, has impeded the progress in the field. We previously reported that &#x00394;DCN, a truncated isoform of matricellular proteoglycan decorin (DCN), is expressed on the surface of mouse ASCs.<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> This isoform lacks the N-terminal segment and is free of the glycosaminoglycan chain. A cyclic peptide with the sequence CSWKYWFGEC (termed WAT7) isolated from a combinatorial peptide library based on its ASC homing was shown to bind &#x00394;DCN.<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> Whereas full-length DCN, expressed in many organs, is exported extracellularly to crosslink collagen, the non-glycanated isoform, &#x00394;DCN, is generated in WAT and is exposed on ASC surface. We showed that CSWKYWFGEC is specific for ASCs and does not recognize MSCs in other organs.<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref></p><p>Based on the ability of CSWKYWFGEC to undergo ASC internalization,<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> by analogy with our previous studies,<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref> we designed a bimodal&#x000a0;peptide D-WAT composed of CSWKYWFGEC and of the KLAKLAKKLAKLAK domain linked via aminohexanoic acid. To circumvent the problem of short half-life of peptides in&#x000a0;vivo due to proteolytic degradation, D-WAT is synthesized with all amino acids as D-enantiomers, which are not recognized by proteases and the immune system.<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> D-WAT has a dose-dependent and specific cytotoxicity toward ASCs adherent in culture, whereas other cell types were not affected.<xref rid="bib25" ref-type="bibr">25</xref>, <xref rid="bib29" ref-type="bibr">29</xref> In&#x000a0;vivo, using flow cytometry and immunofluorescence (IF), we demonstrated depletion of ASCs, but not of MSCs, in other organs. In the mouse model, ASC depletion expectedly resulted in WAT growth suppression and adipose tissue browning.<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref> Recently, we reported that targeting ASCs via &#x00394;DCN also suppresses tumor growth.<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> In that report, we demonstrated that D-WAT treatment specifically depletes tumor stromal and perivascular cells without directly killing malignant cells or tumor-infiltrating leukocytes. ASC cytoablation reduced tumor vascularity and cell proliferation, hence causing hemorrhaging, necrosis, and tumor growth suppression in several mouse carcinoma models. We also validated a D-WAT derivative with a pro-apoptotic domain KFAKFAK<sub>2</sub> that had higher cytoablative activity.</p><p>Whereas our previous studies have demonstrated that ASCs can serve as a drug target in mouse models, the clinical relevance of the discovery of CSWKYWFGEC peptide and &#x00394;DCN has been unclear. Because DCN is evolutionary conserved,<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> we investigated whether there is a human isoform serving as an ASC marker. Here, we present data revealing the expression of non-glycanated (ngDCN) fragment of human DCN, an equivalent of &#x00394;DCN, on both subcutaneous (s.c.) and intraperitoneal (i.p.) visceral ASCs. We show that CSWKYWFGEC can be used as a probe to identify ASCs not only in mouse but also in human WAT and tumors. Finally, we show that human ngDCN is also targeted by CSWKYWFGEC-directed hunter-killer peptides, thus enabling depletion of human PDGFR&#x003b2;<sup>+</sup> ASCs.</p></sec><sec id="sec2"><title>Results</title><sec id="sec2.1"><title>Peptide CSWKYWFGEC as a Probe to Identify ASCs in Tissue Sections</title><p>To investigate whether a DCN isoform recognized by CSWKYWFGEC exists in humans, we tested whether this peptide can serve as a probe similar to an antibody. As a proof of principle, we tested this approach to identify ASCs in mouse paraffin tissue sections using CSWKYWFGEC peptide. Deparaffinized sections were incubated with biotinylated CSWKYWFGEC and subsequently with a streptavidin-fluorophore conjugate. As shown in <xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>A, the peptide bound to PDGFR&#x003b2;-expressing cells in WAT, as expected. Importantly, by incubating the peptide with sections of RM1 adenocarcinoma tumors grown in mice, we demonstrated that it binds to a sub-population of cells in tumor stroma (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>C). This indicates that some of the tumor-recruited ASCs may serve as a direct target of CSWKYWFGEC-directed hunter-killer peptides. To validate peptide specificity, we incubated it with tissues from mice treated with an ASC-targeted hunter-killer peptide WAT7-KFAKFAK<sub>2</sub> (here termed D-CAN), which we reported previously.<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> As expected, the frequency of cells bound with CSWKYWFGEC and expressing PDGFR&#x003b2; was&#x000a0;dramatically reduced after D-WAT treatment (<xref rid="fig1" ref-type="fig">Figures 1</xref>B&#x02013;1E). This indicates that peptide CSWKYWFGEC specifically identifies &#x00394;DCN-expressing cells in IF applications.<fig id="fig1"><label>Figure&#x000a0;1</label><caption><p>CSWKYWFGEC Peptide Probe Identifies ASC in Mouse WAT and Tumors</p><p>Prostate adenocarcinoma RM1 allografts grown in immunocompetent mice treated with PBS (A and C) or ASC-targeting peptide D-WAT (B and D). WAT (A and B) and tumor (C and D) sections were incubated with biotinylated ASC-binding peptide CSWKYWFGEC and then subjected to immunofluorescence with antibodies specific for mouse PDGFR&#x003b2; (red) to localize ASCs and with streptavidin (green) to localize the CSWKYWFGEC peptide. Note CSWKYWFGEC signal on PDGFR&#x003b2;-expressing ASCs in control WAT and tumors is shown (arrows). Nuclei are blue. The scale bar represents 50&#x000a0;&#x003bc;m. (E) Quantification of data from (A)&#x02013;(D) shows that the frequency of CSWKYWFGEC-bound cells in WAT and tumor capsule is reduced upon D-WAT peptide treatment. Plotted are mean&#x000a0;&#x000b1; SEM for multiple fields (n&#x000a0;= 10). *p&#x000a0;&#x0003c; 0.01 (Student&#x02019;s t&#x000a0;test). Experiments were performed twice with similar results.</p></caption><graphic xlink:href="gr1"/></fig></p></sec><sec id="sec2.2"><title>Human ASCs Express Non-glycanated DCN Recognized by CSWKYWFGEC</title><p>Comparison of mouse and human DCN amino termini revealed the high ortholog similarity. Specifically, the positions of cysteines forming disulfide bonds downstream of the glycanation site and the site of mouse DCN cleavage resulting in &#x00394;DCN showing disulfide bonds and the cleavage site in mouse DCN were conserved (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>A). Based on that, we predicted that cleavage of human DCN may take place. To test this directly, we extracted proteins from ASCs derived from s.c. and i.p. WAT of three bariatric surgery patients. Membrane proteins were incubated with CSWKYWFGEC-conjugated beads or deactivated unloaded beads as a negative control. After washing, eluted proteins were subjected to immunoblotting with anti-human decorin antibodies. This revealed the presence of the core DCN band and a smaller band corresponding in size to &#x00394;DCN specifically pulled down with CSWKYWFGEC (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>B). Expression of the two DCN isoforms was confirmed for both s.c. and i.p. of different patients analyzed (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S1</xref>A). We also performed immunoblotting with anti-human DCN antibodies directly on ASC extracts. Each of the two ngDCN forms was more abundant than glycanated DCN (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>C). Human breast cancer cell line MDA-MB-231 used as a negative control was analyzed in parallel. There was no non-glycanated DCN bands observed in proteins extracted from MDA-MB-231 cells (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>C). Non-glycanated DCN was also undetectable in other human cell lines, including PC3 and DU145 prostate adenocarcinoma, HepG2 liver adenocarcinoma, and HEK293 embryonic kidney cells (<xref rid="mmc1" ref-type="supplementary-material">Figures S1</xref>A and S1B). This indicates that, like in mice, human ngDCN is selectively expressed by ASCs.<fig id="fig2"><label>Figure&#x000a0;2</label><caption><p>Human ASCs Express Non-glycanated DCN that Binds to CSWKYWFGEC</p><p>(A) A fragment of mouse and human DCN showing disulfide bonds and the cleavage site in mouse DCN. N-terminal and C-terminal sequences, as well as sequence downstream of GAG attachment site, are abbreviated (&#x02026;). (B) Membrane proteins extracted from s.c. ASCs of a bariatric surgery patient 1 were incubated with CSWKYWFGEC-conjugated beads or control deactivated unconjugated beads. After washing, eluted proteins were subjected to immunoblotting with anti-human decorin antibodies. (C) Proteins extracted from s.c. ASCs of a bariatric surgery patient 2 and human breast adenocarcinoma cells (MDA-MB-231) were subjected to immunoblotting with anti-human decorin antibodies. Arrow points to the band doublet, where the upper band is the core decorin. ] indicates glycanated decorin. Experiments were performed for i.p. and s.c. WAT of three patients with similar results.</p></caption><graphic xlink:href="gr2"/></fig></p></sec><sec id="sec2.3"><title>CSWKYWFGEC Peptide as a Probe Binding Human ASCs</title><p>We then tested whether peptide CSWKYWFGEC can specifically identify mouse and human ngDCN in IF applications. First, we demonstrated peptide binding specificity by comparing wild-type (WT) and DCN-null mouse embryonic fibroblasts (MEFs).<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref> Cells growing in culture were incubated with biotinylated CSWKYWFGEC and then with streptavidin-Cy3 conjugate. Upon washing, notably higher binding of CSWKYWFGEC to WT MEFs was observed, whereas a control peptide CWLGEWLGC mimicking the &#x003b2;1 integrin-interacting protein SPARC<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref> displayed no selectivity (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S1</xref>C). We then compared peptide binding to human ASCs and PC3 prostate adenocarcinoma cells used as a negative control. CSWKYWFGEC bound to the surface of ASC, whereas signal on PC3 cells was very low (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>A). We preformed the same experiment with a scrambled peptide CWWGSFYEKC and an unrelated brown fat-homing peptide (BAT8) reported previously.<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref> The two biotinylated control peptides did not bind to human ASCs (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>A), confirming that CSWKYWFGEC binding is specific. We also generated DCN-null human ASCs using the CRISPR/Cas9 approach to demonstrate that&#x000a0;CSWKYWFGEC binding is contingent on DCN expression (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>B). Indeed, biotinylated CSWKYWFGEC bound to unmodified ASCs, whereas the signal on DCN-knockout (KO) ASCs was dramatically reduced (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>C). Furthermore, we used CSWKYWFGEC peptide as a probe on paraffin sections of human tissues. An array of human organs was analyzed. Strikingly, CSWKYWFGEC showed binding to&#x000a0;stromal cells in both s.c. WAT (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>A) and periprostatic i.p. WAT (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S2</xref>A), whereas the scrambled peptide (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>B) or a&#x000a0;control peptide BAT8 (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S2</xref>B) did not bind to cells of WAT.&#x000a0;Importantly, CSWKYWFGEC displayed no binding to cells of lung (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>C) or other control organs, including spleen, heart, skeletal muscle, pancreas, kidney, liver, and brain (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S2</xref>A). We&#x000a0;also analyzed peptide binding to human breast cancer tissues. CSWKYWFGEC bound to stroma in WAT surrounding the tumor as well as to tumor stromal cells (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>D). CSWKYWFGEC binding to tumor stromal cells was observed for different cancer subtypes and grades (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S3</xref>).<fig id="fig3"><label>Figure&#x000a0;3</label><caption><p>CSWKYWFGEC Binds to ngDCN on Human ASC Surface</p><p>(A) Live human ASCs from s.c. WAT of a bariatric surgery patient 1 and prostate adenocarcinoma cells (PC3) cells were incubated with 20&#x000a0;nM biotinylated CSWKYWFGEC, a scrambled peptide CWWGSFYEKC, or a control biotinylated peptide (BAT8). After incubation in 10% FBS/DMEM media for 2&#x000a0;hr, washing, and fixation, cells were incubated with streptavidin-Cy3 and stained with DAPI. Plotted are mean&#x000a0;&#x000b1; SEM for multiple fields (n&#x000a0;= 10). *p&#x000a0;&#x0003c; 0.01 (Student&#x02019;s t test). (B) Anti-DCN immunoblotting on protein extracts from human ASCs in which DCN was deleted (KO) and wild-type parental ASCs (WT) used as control. &#x003b2;- tubulin, loading control. (C) Live human DCN null and control ASCs were incubated with 20&#x000a0;nM biotinylated CSWKYWFGEC. After incubation in 10% FBS/DMEM media for 2&#x000a0;hr, washing, and fixation, cells were incubated with streptavidin-Cy3 and stained with DAPI. Nuclei are blue. The scale bar represents 50&#x000a0;&#x003bc;m. Plotted are mean&#x000a0;&#x000b1; SEM for multiple fields (n&#x000a0;= 10). *p&#x000a0;&#x0003c; 0.01 (Student&#x02019;s t test). Experiments were performed for i.p. and s.c. WAT of three patients with similar results.</p></caption><graphic xlink:href="gr3"/></fig><fig id="fig4"><label>Figure&#x000a0;4</label><caption><p>CSWKYWFGEC as a Probe to Identify ASCs in Human WAT and Tumors</p><p>Paraffin sections of indicated human tissues were incubated with biotinylated CSWKYWFGEC peptide or a scrambled peptide CWWGSFYEKC and subjected to&#x000a0;IF with antibodies against CD31 (green) and streptavidin (red). Note that the scrambled peptide does not bind to WAT (B), whereas CSWKYWFGEC-bound cells are observed in s.c. WAT (A) and tumor stroma (D), but not in the lung (C). Nuclei are blue. The scale bar represents 50&#x000a0;&#x003bc;m. Experiments were performed for WAT of three patients with similar results.</p></caption><graphic xlink:href="gr4"/></fig></p></sec><sec id="sec2.4"><title>Human ASC Targeting with a Hunter-Killer Peptide</title><p>Next, we tested whether ngDCN-homing hunter killer peptides could be used for human ASC ablation. We incubated human ASCs and control cells with increasing concentrations of peptide D-CAN that has been shown to kill mouse ASCs.<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> Trypan blue exclusion assay was used to assess cell death. At the concentration of 0.05&#x000a0;mM, previously reported effective for mouse ASC,<xref rid="bib25" ref-type="bibr">25</xref>, <xref rid="bib29" ref-type="bibr">29</xref> D-CAN also killed &#x0223c;50% of human ASCs (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>A). Importantly, control human cell lines were not killed by D-CAN at the concentration lethal for ASCs (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>A). Both subcutaneous and visceral ASCs from three different patients were confirmed to be sensitive to D-CAN treatment (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S4</xref>A). Untargeted pro-apoptotic domain did not cause cell death at that concentration and killed cells only nonspecifically starting at 1&#x000a0;mM (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S4</xref>B). Importantly, by using human DCN-null ASCs (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>B), we showed that D-CAN kills only cells that express DCN (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>B). Finally, we tested whether CSWKYWFGEC peptide kills a sub-population of human ASCs with a selectivity reported in mice.<xref rid="bib25" ref-type="bibr">25</xref>, <xref rid="bib29" ref-type="bibr">29</xref> By analyzing sections derived from bariatric surgery patients, we discovered that human WAT contains PDGFR&#x003b1;<sup>+</sup>PDGFR&#x003b2;<sup>&#x02212;</sup> ASCs in the stroma and PDGFR&#x003b1;<sup>&#x02212;</sup>PDGFR&#x003b2;<sup>+</sup> ASCs in close association with the blood vessel lumen (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>A). Thus, human WAT has two sub-populations of ASCs that we previously reported in mice.<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref> Like in mice, D-WAT peptide killed some, but not all, human ASCs in cell culture, as revealed by trypan blue staining (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>B). To identify the sensitive ASC sub-population, we performed IF with PDGFR&#x003b1; and PDGFR&#x003b2; antibodies while also immuno-detecting cleaved caspase 3 (a marker of apoptosis). Colocalization studies clearly showed that D-WAT induced apoptosis of PDGFR&#x003b2;<sup>+</sup>, but not of PDGFR&#x003b1;<sup>+</sup>, ASCs. We conclude that, like in mice, ngDCN is selectively expressed on PDGFR&#x003b1;<sup>&#x02212;</sup>PDGFR&#x003b2;<sup>+</sup> ASCs that can be targeted with CSWKYWFGEC-directed hunter killer peptides.<fig id="fig5"><label>Figure&#x000a0;5</label><caption><p>Hunter-Killer Peptide Targeting Human ASCs Expressing DCN</p><p>(A) Human subcutaneous ASCs from patient 1, breast adenocarcinoma (MDA-MB-231), and prostate adenocarcinoma (PC3 and DU145) cells were incubated with indicated concentrations of peptide D-CAN. Plotted are mean&#x000a0;&#x000b1; SEM for multiple fields (n&#x000a0;= 10). *p&#x000a0;&#x0003c; 0.01 (Student&#x02019;s t test). (B) Human unmodified ASCs and DCN-null ASCs (DCN-KO) were incubated with indicated concentrations of peptide D-CAN. After 4&#x000a0;hr treatment, cells were stained with trypan blue. Blue color shows selective killing of ASCs at 0.05&#x000a0;mM. The scale bar represents 50&#x000a0;&#x003bc;m. Plotted are mean&#x000a0;&#x000b1; SEM for multiple fields (n&#x000a0;= 10). *p&#x000a0;&#x0003c; 0.01 (Student&#x02019;s t test). Experiments were performed for i.p. and s.c. WAT of three patients with similar results.</p></caption><graphic xlink:href="gr5"/></fig><fig id="fig6"><label>Figure&#x000a0;6</label><caption><p>Selective Human PDGFR&#x003b2;<sup>+</sup> ASC Depletion with the Hunter-Killer Peptide</p><p>(A) IF of human WAT identifies PDGFR&#x003b1;<sup>+</sup>PDGFR&#x003b2;<sup>&#x02212;</sup> and&#x000a0;PDGFR&#x003b1;<sup>&#x02212;</sup>PDGFR&#x003b2;+ ASCs as distinct populations located around a blood vessel (*, green autofluorescence). (B) Selective apoptosis of some, but not all, ASCs from human WAT treated with 0.01&#x000a0;mM control peptide or D-WAT is shown. Trypan blue staining (blue) reveals cell death. Plotted are mean&#x000a0;&#x000b1; SEM for multiple fields (n&#x000a0;= 10). *p&#x000a0;&#x0003c; 0.01 (Student&#x02019;s t test). (C) IF on cells from (B) identifies apoptosis (cleaved caspase 3, green) of PDGFR&#x003b2;<sup>+</sup> cells (yellow), but not of PDGFR&#x003b1;<sup>+</sup> cells (red) induced by 0.01&#x000a0;mM D-WAT. The scale bar represents 50&#x000a0;&#x003bc;m. Plotted are mean&#x000a0;&#x000b1; SEM for multiple fields (n&#x000a0;= 10). *p&#x000a0;&#x0003c; 0.01 (Student&#x02019;s t test). Experiments were performed for i.p. and s.c. WAT of three patients with similar results.</p></caption><graphic xlink:href="gr6"/></fig></p></sec></sec><sec id="sec3"><title>Discussion</title><p>New molecular therapeutics are awaited to effectively suppress cancer aggressiveness and progression to metastatic stage. Inability of available drugs to overcome the resistance of cancer to treatment indicates the existence of untargeted cell populations driving the disease. Growth and metastasis of solid tumors relies on the tumor stroma, the infiltrating non-malignant fibroblastoid cells.<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib33" ref-type="bibr">33</xref> Disease progression is driven by these stromal cells<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> that secrete trophic factors<xref rid="bib34" ref-type="bibr">34</xref>, <xref rid="bib35" ref-type="bibr">35</xref>, <xref rid="bib36" ref-type="bibr">36</xref> and mediate the desmoplastic deposition of extracellular matrix (ECM), tumor vascularization, and the epithelial-mesenchymal transition (EMT) enabling metastatic capacity.<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref> Tumor stroma also mutes anti-cancer immune response.<xref rid="bib38" ref-type="bibr">38</xref>, <xref rid="bib39" ref-type="bibr">39</xref>, <xref rid="bib40" ref-type="bibr">40</xref>, <xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref> Progression of many types of cancer is promoted by obesity, hallmark of which is WAT overgrowth and high BMI.<xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib16" ref-type="bibr">16</xref>, <xref rid="bib43" ref-type="bibr">43</xref> The mechanisms underlying increased risk of cancer mortality in obese patients remain unclear. Whereas diet<xref rid="bib44" ref-type="bibr"><sup>44</sup></xref> and the metabolic syndrome<xref rid="bib45" ref-type="bibr"><sup>45</sup></xref> appear to underlie cancer initiation, different mechanisms account for the effect of obesity on cancer progression. A growing body of evidence indicates that the key determinant of cancer progression in obesity is WAT.<xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib46" ref-type="bibr">46</xref> Consistent with that observation, breast cancer survivors that undergo WAT transplantation for breast augmentation have a higher chance of relapse, as we have reported.<xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib16" ref-type="bibr">16</xref>, <xref rid="bib17" ref-type="bibr">17</xref> Factors secreted by ASCs, adipocytes, and infiltrating leukocytes, collectively called adipokines, have been considered as the mechanistic link between obesity and cancer.<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref> ASCs also secrete MCP-1 and other&#x000a0;chemokines recruiting macrophages<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref> that accumulate in the crown-like structures associated with breast cancer risk and progression.<xref rid="bib49" ref-type="bibr">49</xref>, <xref rid="bib50" ref-type="bibr">50</xref></p><p>At present, there are no therapies aimed at ASCs available due to the lack of validated molecular targets specific for these cells. Previously, we reported non-glycanated &#x00394;DCN as the marker of ASC differentiating into white adipocytes in mice.<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref> Here, we demonstrate that human ASC express also non-glycanated DCN recognized by CSWKYWFGEC peptide. We show that this peptide can be used as an imaging probe or a vehicle directing cytotoxic therapeutics to ASCs and enabling their targeted depletion. We had previously reported that, in mice, ngDCN-homing hunter killer peptides D-WAT and D-CAN target PDGFR&#x003b1;-negative/PDGFR&#x003b2;-positive ASCs serving as progenitors of white adipocytes, whereas they spare the PDGFR&#x003b1;-positive/PDGFR&#x003b2;-negative brown/beige adipocyte progenitors.<xref rid="bib25" ref-type="bibr">25</xref>, <xref rid="bib29" ref-type="bibr">29</xref> Our data presented here indicate that both D-WAT and D-CAN also target human ASCs with comparable selectivity. As we had demonstrated in animal studies, ASCs with higher PDGFR&#x003b1;/lower PDGFR&#x003b2; signaling give rise to beige adipocytes, whereas ASCs with higher PDGFR&#x003b2;/lower PDGFR&#x003b1; signaling give rise to white adipocytes. It remains to be determined whether ngDCN specifically marks white adipocyte progenitor cells in humans.</p><p>Decorin is a ubiquitously expressed proteoglycan secreted into the extracellular matrix molecules. Its main function is modulation of fibrillogenesis through interaction with collagens and fibronectin.<xref rid="bib51" ref-type="bibr"><sup>51</sup></xref> Based on the DCN cleavage site resulting in &#x00394;DCN, we have predicted that it is generated post-translationally.<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> The protease generating &#x00394;DCN remains to be identified. Our data showing that ngDCN added to cell culture medium binds to human ASCs (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S5</xref>) suggest that proteolysis occurs extracellularly. The function of ngDCN remains to be determined. Both DCN and ngDCN have been reported to suppress adipogenesis;<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> however, the mechanism of their effects on specific pre-adipocyte lineages has not been analyzed. It has been shown that DCN suppresses PDGFR signaling by interfering with PDGF activity.<xref rid="bib52" ref-type="bibr"><sup>52</sup></xref> In mice, PDGFR&#x003b1;<sup>&#x02212;</sup>PDGFR&#x003b2;<sup>+</sup> ASCs are perivascular/mural cells, whereas the PDGFR&#x003b1;<sup>+</sup>PDGFR&#x003b2;<sup>&#x02212;</sup> cells are localized deeper in the stroma.<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref> Our data demonstrate that, in&#x000a0;human WAT, the two corresponding stromal populations exist and have the same relative perivascular localization. It is possible that DCN and ngDCN regulate adipogenesis by suppressing signaling specifically through PDGFR&#x003b1; or PDGFR&#x003b2;. The function of DCN and ngDCN interactors, including PDGFs, transforming growth factor &#x003b2; (TGF-&#x003b2;), and resistin, which serves as a &#x00394;DCN receptor in WAT,<xref rid="bib26" ref-type="bibr">26</xref>, <xref rid="bib51" ref-type="bibr">51</xref> in modulating ASC fate remains to be tested. Studies in mouse models provide evidence that DCN suppresses PDGFR&#x003b1; signaling in liver cancer.<xref rid="bib52" ref-type="bibr"><sup>52</sup></xref> Establishing how DCN and ngDCN modulates PDGFR&#x003b1; and PDGFR&#x003b2; signaling in the context of white and brown adipose tissue, tumors, and other fibrotic conditions may delineate new approaches to disease prevention and treatment.</p><p>In summary, this study identifies a cell surface marker through which human ASCs can be identified and depleted. We propose that development of drugs targeting human ASCs can lead to improved combination therapies complementing conventional cancer treatments in cancer patients.</p></sec><sec id="sec4"><title>Materials and Methods</title><sec id="sec4.1"><title>Human Subjects</title><p>The clinical protocol was approved by the institutional review board (IRB) (protocol HSC-MS-14-0514). For ASC isolation, samples of subcutaneous and omental WAT from three de-identified patients undergoing bariatric surgery (coded as patients 1, 2, and 3) were used with similar results. Paraffin sections analyzed were from WAT of patients 1&#x02013;3 and from 12 additional patients. Paraffin sections of eight control normal tissues were from human adult multi-tissue panel-I T8234431 (BioChain). Paraffin sections were from the three breast cancer patients (invasive ductal carcinoma [IDC] grade 3 estrogen receptor [ER]<sup>+</sup>progesterone receptor[PR]<sup>&#x02212;</sup> stage 3 breast cancer, ductal carcinoma in&#x000a0;situ [DCIS] grade 3 ER<sup>&#x02212;</sup>PR<sup>&#x02212;</sup> stage 0 breast cancer, and IDC grade 2 ER<sup>+</sup>PR<sup>+</sup> stage 1 breast cancer) enrolled at MD Anderson Cancer Center and from periprostatic WAT specimens described previously.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref></p></sec><sec id="sec4.2"><title>Experimental Animals</title><p>Animal studies were approved by the Institutional Animal Care and Use Committee of UTHealth. C57BL/6 mice were from Jackson Laboratory. For RM1 tumor cell grafting, 1&#x000a0;&#x000d7; 10<sup>5</sup> cells were injected with a 21-gauge needle s.c. onto lower back.</p></sec><sec id="sec4.3"><title>Peptides</title><p>Proteolysis-resistant WAT7-KLAKLAK<sub>2</sub> (D-WAT) and WAT7-KFAKFAK<sub>2</sub> (D-CAN) were made as &#x0201c;all-D-amino acid&#x0201d; peptides with the targeting and apoptotic domains linked by aminohexanoic acid linker NH-(CH<sub>2</sub>)<sub>5</sub>-CO. Peptides were synthesized as acetate salt, cysteine cyclized, chromatographically purified to 99%, and quality&#x000a0;controlled (mass spectroscopy). D-WAT, CSWKYWFGEC, and NH-(CH<sub>2</sub>)<sub>5</sub>-KLAKLAK<sub>2</sub> peptides were purchased from Celtek; D-CAN was purchased from Ambiopharm. Peptides were dissolved in PBS to 10&#x000a0;mM, and aliquots were stored frozen until dilution in PBS, filtration, and use. For peptide administration into mice, the metronomic s.c. injection protocol was used as described,<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref> starting the day after tumor grafting. Peptide biotinylation was performed as described.<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> Tissues and live cells were incubated with biotinylated peptides at concentration 10&#x000a0;nM and 20&#x000a0;nM, respectively.</p></sec><sec id="sec4.4"><title>Affinity Chromatography</title><p>Protein pull-down assay was performed as described.<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> Cells were disrupted in PBS containing protease inhibitors (PI) cocktail with a&#x000a0;Dounce homogenizer; centrifugation (15,000&#x000a0;&#x000d7; <italic>g</italic> for 30&#x000a0;min at 4&#x000b0;C) was performed to separate soluble proteins from membrane pellet. Membrane proteins were solubilized in PBS containing 1&#x000a0;mM CaCl<sub>2</sub>, 1&#x000a0;mM MgCl<sub>2</sub>, 50&#x000a0;mM n-octyl-beta-D-glucopyranoside, and PI cocktail (column buffer). Six milligrams of a cysteine-cyclized peptide was coupled onto 250&#x000a0;&#x003bc;L of Affigel 10 (Bio-Rad), and the column was equilibrated with column buffer containing 1% Triton X-100. Peptide-coupled resin (10&#x000a0;&#x003bc;L) was incubated with 30&#x000a0;&#x003bc;g of membrane extract and washed with column buffer. Elution was performed with SDS-PAGE loading buffer. Protein preparations resolved on SDS-PAGE were blotted onto Immobilon-FL membrane (Millipore), blocked with Odyssey blocking buffer (LI-COR Biosciences), and probed (in PBS/0.05% Triton X-100) with 1:1,000 goat anti-DCN (R&#x00026;D Systems). Signal was detected by Odyssey imaging system using anti-goat IRDye 800CW (LI-COR Biosciences). NS0-expressed murine DCN was from R&#x00026;D Systems.</p></sec><sec id="sec4.5"><title>Cell Lines and Primary Cell Culture</title><p>Cells were cultured in DMEM supplemented with 10% fetal bovine&#x000a0;serum (FBS) and penicillin-streptomycin. Cell lines were purchased from the American Type Culture Collection. Primary&#x000a0;cells were isolated and cultured as described.<xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib26" ref-type="bibr">26</xref> Freshly isolated ASCs were briefly cultured to remove non-adherent cells.&#x000a0;Trypan blue exclusion assay was used to determine cell viability in peptide-treated ASCs and tumor cell lines as reported&#x000a0;previously.<xref rid="bib25" ref-type="bibr">25</xref>, <xref rid="bib29" ref-type="bibr">29</xref> When cell density reached 80% confluency,&#x000a0;cells were treated with indicated concentrations of peptides in 0.5&#x000a0;mL culture medium for 2&#x000a0;hr. Cells were stained with 0.4% trypan blue solution (MP Biomedicals) for 10&#x000a0;min to visualize live and&#x000a0;dead cells. DCN-null ASCs were generated from primary s.c. human ASCs of patient 1 using the CRISPR/Cas9 method.<xref rid="bib53" ref-type="bibr"><sup>53</sup></xref> To construct <italic>pLenti-CRISPR/Cas9 hDCN</italic> gRNA expression vectors, the 20-bp target sequence 5&#x02032;- GGCTCGAAGTCGCGGTCATC<underline>AGG</underline>-3&#x02032; containing the PAM sequence (underlined) was subcloned into <italic>lenti-CRISPR v2</italic> plasmid (Addgene no. 52961).</p></sec><sec id="sec4.6"><title>IF</title><p>Sections of formalin-fixed paraffin-embedded tissues were analyzed by IF as described.<xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib26" ref-type="bibr">26</xref> Antigen retrieval, washing with 0.2% Triton X-100, and blocking in Serum-Free Protein Block (Dako) was followed by incubation with primary antibodies (4&#x000b0;C; 12&#x000a0;hr) and secondary antibodies (room temperature [RT]; 1&#x000a0;hr) in PBS containing 0.05% Tween 20. Cells&#x000a0;plated on 24-well plate were fixed with&#x000a0;4% paraformaldehyde, permeabilized with Triton X-100, blocked with Serum-Free Protein Block, and followed by incubation with primary and secondary antibodies, as above. Antibodies used were as follows: rabbit&#x000a0;anti-mouse PDGFR&#x003b2; ab32570 (Abcam; 1:100); rabbit anti-CD31 (Santa Cruz Biotechnology;&#x000a0;1:100); goat anti-human PDGFR&#x003b1; (R&#x00026;D; 1:100); rabbit anti-human PDGFR&#x003b2; (Abcam; 1:100); and rabbit anti-Asp175-cleaved caspase3 from Cell Signaling Technology (1:100). Alexa-488-conjugated (1:150) and Cy3-conjugated (1:100) streptavidin was from Invitrogen. Secondary antibodies were donkey Alexa-488-conjugated (1:150) immunoglobulin G (IgG) from Invitrogen and Cy3-conjugated (1:300) IgG from Jackson ImmunoResearch. Nuclei were visualized with DAPI. For quantifications, at least ten random 10&#x000d7; or 20&#x000d7; magnification fields were blindly scored and/or measured using microscope grid. Tissue IF images were acquired with Carl Zeiss upright Apotome Axio Imager Z1/ZEN2 Core Imaging software. Cells were imaged using a Leica microscope (Leica Microsystems; model: DM IL LED Fluo).</p></sec><sec id="sec4.7"><title>Statistics</title><p>Microsoft Excel was used to graph data as mean&#x000a0;&#x000b1; SEM and to calculate p values using homoscedastic Student&#x02019;s t test.</p></sec></sec><sec id="sec5"><title>Author Contributions</title><p>M.G.K. designed the experiments, analyzed data, and wrote the manuscript; A.C.D. designed and conducted the experiments and analyzed data; A.D. conducted the experiments; and B.S., X.W., A.A.S., and N.T.U. provided materials, analyzed data, and edited the manuscript.</p></sec><sec id="sec6"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Kolonin</surname><given-names>M.G.</given-names></name><name><surname>Evans</surname><given-names>K.W.</given-names></name><name><surname>Mani</surname><given-names>S.A.</given-names></name><name><surname>Gomer</surname><given-names>R.H.</given-names></name></person-group><article-title>Alternative origins of stroma in normal organs and disease</article-title><source>Stem Cell Res. (Amst.)</source><volume>8</volume><year>2012</year><fpage>312</fpage><lpage>323</lpage></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>T.</given-names></name><name><surname>Tseng</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Sirin</surname><given-names>O.</given-names></name><name><surname>Corn</surname><given-names>P.G.</given-names></name><name><surname>Li-Ning-Tapia</surname><given-names>E.M.</given-names></name><name><surname>Troncoso</surname><given-names>P.</given-names></name><name><surname>Davis</surname><given-names>J.</given-names></name><name><surname>Pettaway</surname><given-names>C.</given-names></name><name><surname>Ward</surname><given-names>J.</given-names></name></person-group><article-title>CXCL1 mediates obesity-associated adipose stromal cell trafficking and function in the tumour microenvironment</article-title><source>Nat. Commun.</source><volume>7</volume><year>2016</year><fpage>11674</fpage><lpage>11690</lpage><pub-id pub-id-type="pmid">27241286</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Daquinag</surname><given-names>A.</given-names></name><name><surname>Traktuev</surname><given-names>D.O.</given-names></name><name><surname>Amaya-Manzanares</surname><given-names>F.</given-names></name><name><surname>Simmons</surname><given-names>P.J.</given-names></name><name><surname>March</surname><given-names>K.L.</given-names></name><name><surname>Pasqualini</surname><given-names>R.</given-names></name><name><surname>Arap</surname><given-names>W.</given-names></name><name><surname>Kolonin</surname><given-names>M.G.</given-names></name></person-group><article-title>White adipose tissue cells are recruited by experimental tumors and promote cancer progression in mouse models</article-title><source>Cancer Res.</source><volume>69</volume><year>2009</year><fpage>5259</fpage><lpage>5266</lpage><pub-id pub-id-type="pmid">19491274</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Klopp</surname><given-names>A.H.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Solley</surname><given-names>T.</given-names></name><name><surname>Amaya-Manzanares</surname><given-names>F.</given-names></name><name><surname>Marini</surname><given-names>F.</given-names></name><name><surname>Andreeff</surname><given-names>M.</given-names></name><name><surname>Debeb</surname><given-names>B.</given-names></name><name><surname>Woodward</surname><given-names>W.</given-names></name><name><surname>Schmandt</surname><given-names>R.</given-names></name><name><surname>Broaddus</surname><given-names>R.</given-names></name></person-group><article-title>Omental adipose tissue-derived stromal cells promote vascularization and growth of endometrial tumors</article-title><source>Clin. Cancer Res.</source><volume>18</volume><year>2012</year><fpage>771</fpage><lpage>782</lpage><pub-id pub-id-type="pmid">22167410</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Daquinag</surname><given-names>A.C.</given-names></name><name><surname>Amaya-Manzanares</surname><given-names>F.</given-names></name><name><surname>Sirin</surname><given-names>O.</given-names></name><name><surname>Tseng</surname><given-names>C.</given-names></name><name><surname>Kolonin</surname><given-names>M.G.</given-names></name></person-group><article-title>Stromal progenitor cells from endogenous adipose tissue contribute to pericytes and adipocytes that populate the tumor microenvironment</article-title><source>Cancer Res.</source><volume>72</volume><year>2012</year><fpage>5198</fpage><lpage>5208</lpage><pub-id pub-id-type="pmid">23071132</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Kolonin</surname><given-names>M.G.</given-names></name><name><surname>Simmons</surname><given-names>P.J.</given-names></name></person-group><article-title>Combinatorial stem cell mobilization</article-title><source>Nat. Biotechnol.</source><volume>27</volume><year>2009</year><fpage>252</fpage><lpage>253</lpage><pub-id pub-id-type="pmid">19270674</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Bellows</surname><given-names>C.F.</given-names></name><name><surname>Kolonin</surname><given-names>M.G.</given-names></name></person-group><article-title>Adipose tissue-derived progenitor cells and cancer</article-title><source>World J. Stem Cells</source><volume>2</volume><year>2010</year><fpage>103</fpage><lpage>113</lpage><pub-id pub-id-type="pmid">21607127</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Bellows</surname><given-names>C.F.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Frazier</surname><given-names>M.L.</given-names></name><name><surname>Kolonin</surname><given-names>M.G.</given-names></name></person-group><article-title>Circulation of progenitor cells in obese and lean colorectal cancer patients</article-title><source>Cancer Epidemiol. Biomarkers Prev.</source><volume>20</volume><year>2011</year><fpage>2461</fpage><lpage>2468</lpage><pub-id pub-id-type="pmid">21930958</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Bellows</surname><given-names>C.F.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Simmons</surname><given-names>P.J.</given-names></name><name><surname>Khalsa</surname><given-names>A.S.</given-names></name><name><surname>Kolonin</surname><given-names>M.G.</given-names></name></person-group><article-title>Influence of BMI on level of circulating progenitor cells</article-title><source>Obesity (Silver Spring)</source><volume>19</volume><year>2011</year><fpage>1722</fpage><lpage>1726</lpage><pub-id pub-id-type="pmid">21293449</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Kidd</surname><given-names>S.</given-names></name><name><surname>Spaeth</surname><given-names>E.</given-names></name><name><surname>Watson</surname><given-names>K.</given-names></name><name><surname>Burks</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>H.</given-names></name><name><surname>Klopp</surname><given-names>A.</given-names></name><name><surname>Andreeff</surname><given-names>M.</given-names></name><name><surname>Marini</surname><given-names>F.C.</given-names></name></person-group><article-title>Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma</article-title><source>PLoS ONE</source><volume>7</volume><year>2012</year><fpage>e30563</fpage><pub-id pub-id-type="pmid">22363446</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Martin-Padura</surname><given-names>I.</given-names></name><name><surname>Gregato</surname><given-names>G.</given-names></name><name><surname>Marighetti</surname><given-names>P.</given-names></name><name><surname>Mancuso</surname><given-names>P.</given-names></name><name><surname>Calleri</surname><given-names>A.</given-names></name><name><surname>Corsini</surname><given-names>C.</given-names></name><name><surname>Pruneri</surname><given-names>G.</given-names></name><name><surname>Manzotti</surname><given-names>M.</given-names></name><name><surname>Lohsiriwat</surname><given-names>V.</given-names></name><name><surname>Rietjens</surname><given-names>M.</given-names></name></person-group><article-title>The white adipose tissue used in lipotransfer procedures is a rich reservoir of CD34+ progenitors able to promote cancer progression</article-title><source>Cancer Res.</source><volume>72</volume><year>2012</year><fpage>325</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">22052460</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>G.</given-names></name><name><surname>Yang</surname><given-names>R.</given-names></name><name><surname>Banie</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Ning</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>L.C.</given-names></name><name><surname>Lue</surname><given-names>T.F.</given-names></name><name><surname>Lin</surname><given-names>C.S.</given-names></name></person-group><article-title>Effects of transplantation of adipose tissue-derived stem cells on prostate tumor</article-title><source>Prostate</source><volume>70</volume><year>2010</year><fpage>1066</fpage><lpage>1073</lpage><pub-id pub-id-type="pmid">20232361</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Orecchioni</surname><given-names>S.</given-names></name><name><surname>Gregato</surname><given-names>G.</given-names></name><name><surname>Martin-Padura</surname><given-names>I.</given-names></name><name><surname>Reggiani</surname><given-names>F.</given-names></name><name><surname>Braidotti</surname><given-names>P.</given-names></name><name><surname>Mancuso</surname><given-names>P.</given-names></name><name><surname>Calleri</surname><given-names>A.</given-names></name><name><surname>Quarna</surname><given-names>J.</given-names></name><name><surname>Marighetti</surname><given-names>P.</given-names></name><name><surname>Aldeni</surname><given-names>C.</given-names></name></person-group><article-title>Complementary populations of human adipose CD34+ progenitor cells promote growth, angiogenesis, and metastasis of breast cancer</article-title><source>Cancer Res.</source><volume>73</volume><year>2013</year><fpage>5880</fpage><lpage>5891</lpage><pub-id pub-id-type="pmid">23918796</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Rowan</surname><given-names>B.G.</given-names></name><name><surname>Gimble</surname><given-names>J.M.</given-names></name><name><surname>Sheng</surname><given-names>M.</given-names></name><name><surname>Anbalagan</surname><given-names>M.</given-names></name><name><surname>Jones</surname><given-names>R.K.</given-names></name><name><surname>Frazier</surname><given-names>T.P.</given-names></name><name><surname>Asher</surname><given-names>M.</given-names></name><name><surname>Lacayo</surname><given-names>E.A.</given-names></name><name><surname>Friedlander</surname><given-names>P.L.</given-names></name><name><surname>Kutner</surname><given-names>R.</given-names></name><name><surname>Chiu</surname><given-names>E.S.</given-names></name></person-group><article-title>Human adipose tissue-derived stromal/stem cells promote migration and early metastasis of triple negative breast cancer xenografts</article-title><source>PLoS ONE</source><volume>9</volume><year>2014</year><fpage>e89595</fpage><pub-id pub-id-type="pmid">24586900</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Bertolini</surname><given-names>F.</given-names></name><name><surname>Petit</surname><given-names>J.Y.</given-names></name><name><surname>Kolonin</surname><given-names>M.G.</given-names></name></person-group><article-title>Stem cells from adipose tissue and breast cancer: hype, risks and hope</article-title><source>Br. J. Cancer</source><volume>112</volume><year>2015</year><fpage>419</fpage><lpage>423</lpage><pub-id pub-id-type="pmid">25584493</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Bertolini</surname><given-names>F.</given-names></name><name><surname>Orecchioni</surname><given-names>S.</given-names></name><name><surname>Petit</surname><given-names>J.Y.</given-names></name><name><surname>Kolonin</surname><given-names>M.G.</given-names></name></person-group><article-title>Obesity, proinflammatory mediators, adipose tissue progenitors, and breast cancer</article-title><source>Curr. Opin. Oncol.</source><volume>26</volume><year>2014</year><fpage>545</fpage><lpage>550</lpage><pub-id pub-id-type="pmid">25279961</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Bertolini</surname><given-names>F.</given-names></name><name><surname>Lohsiriwat</surname><given-names>V.</given-names></name><name><surname>Petit</surname><given-names>J.Y.</given-names></name><name><surname>Kolonin</surname><given-names>M.G.</given-names></name></person-group><article-title>Adipose tissue cells, lipotransfer and cancer: a challenge for scientists, oncologists and surgeons</article-title><source>Biochim. Biophys. Acta</source><volume>1826</volume><year>2012</year><fpage>209</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">22546620</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Nowicka</surname><given-names>A.</given-names></name><name><surname>Marini</surname><given-names>F.C.</given-names></name><name><surname>Solley</surname><given-names>T.N.</given-names></name><name><surname>Elizondo</surname><given-names>P.B.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Sharp</surname><given-names>H.J.</given-names></name><name><surname>Broaddus</surname><given-names>R.</given-names></name><name><surname>Kolonin</surname><given-names>M.</given-names></name><name><surname>Mok</surname><given-names>S.C.</given-names></name><name><surname>Thompson</surname><given-names>M.S.</given-names></name></person-group><article-title>Human omental-derived adipose stem cells increase ovarian cancer proliferation, migration, and chemoresistance</article-title><source>PLoS ONE</source><volume>8</volume><year>2013</year><fpage>e81859</fpage><pub-id pub-id-type="pmid">24312594</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Salimian Rizi</surname><given-names>B.</given-names></name><name><surname>Caneba</surname><given-names>C.</given-names></name><name><surname>Nowicka</surname><given-names>A.</given-names></name><name><surname>Nabiyar</surname><given-names>A.W.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>K.</given-names></name><name><surname>Klopp</surname><given-names>A.</given-names></name><name><surname>Nagrath</surname><given-names>D.</given-names></name></person-group><article-title>Nitric oxide mediates metabolic coupling of omentum-derived adipose stroma to ovarian and endometrial cancer cells</article-title><source>Cancer Res.</source><volume>75</volume><year>2015</year><fpage>456</fpage><lpage>471</lpage><pub-id pub-id-type="pmid">25425006</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Rodeheffer</surname><given-names>M.S.</given-names></name><name><surname>Birsoy</surname><given-names>K.</given-names></name><name><surname>Friedman</surname><given-names>J.M.</given-names></name></person-group><article-title>Identification of white adipocyte progenitor cells in&#x000a0;vivo</article-title><source>Cell</source><volume>135</volume><year>2008</year><fpage>240</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">18835024</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Traktuev</surname><given-names>D.O.</given-names></name><name><surname>Merfeld-Clauss</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Kolonin</surname><given-names>M.</given-names></name><name><surname>Arap</surname><given-names>W.</given-names></name><name><surname>Pasqualini</surname><given-names>R.</given-names></name><name><surname>Johnstone</surname><given-names>B.H.</given-names></name><name><surname>March</surname><given-names>K.L.</given-names></name></person-group><article-title>A population of multipotent CD34-positive adipose stromal cells share pericyte and mesenchymal surface markers, reside in a periendothelial location, and stabilize endothelial networks</article-title><source>Circ. Res.</source><volume>102</volume><year>2008</year><fpage>77</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">17967785</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Berry</surname><given-names>R.</given-names></name><name><surname>Rodeheffer</surname><given-names>M.S.</given-names></name></person-group><article-title>Characterization of the adipocyte cellular lineage in&#x000a0;vivo</article-title><source>Nat. Cell Biol.</source><volume>15</volume><year>2013</year><fpage>302</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">23434825</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>Y.H.</given-names></name><name><surname>Petkova</surname><given-names>A.P.</given-names></name><name><surname>Mottillo</surname><given-names>E.P.</given-names></name><name><surname>Granneman</surname><given-names>J.G.</given-names></name></person-group><article-title>In&#x000a0;vivo identification of bipotential adipocyte progenitors recruited by &#x003b2;3-adrenoceptor activation and high-fat feeding</article-title><source>Cell Metab.</source><volume>15</volume><year>2012</year><fpage>480</fpage><lpage>491</lpage><pub-id pub-id-type="pmid">22482730</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>W.</given-names></name><name><surname>Zeve</surname><given-names>D.</given-names></name><name><surname>Suh</surname><given-names>J.M.</given-names></name><name><surname>Bosnakovski</surname><given-names>D.</given-names></name><name><surname>Kyba</surname><given-names>M.</given-names></name><name><surname>Hammer</surname><given-names>R.E.</given-names></name><name><surname>Tallquist</surname><given-names>M.D.</given-names></name><name><surname>Graff</surname><given-names>J.M.</given-names></name></person-group><article-title>White fat progenitor cells reside in the adipose vasculature</article-title><source>Science</source><volume>322</volume><year>2008</year><fpage>583</fpage><lpage>586</lpage><pub-id pub-id-type="pmid">18801968</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Daquinag</surname><given-names>A.C.</given-names></name><name><surname>Tseng</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Amaya-Manzanares</surname><given-names>F.</given-names></name><name><surname>Florez</surname><given-names>F.</given-names></name><name><surname>Dadbin</surname><given-names>A.</given-names></name><name><surname>Zhang</surname><given-names>T.</given-names></name><name><surname>Kolonin</surname><given-names>M.G.</given-names></name></person-group><article-title>Targeted proapoptotic peptides depleting adipose stromal cells inhibit tumor growth</article-title><source>Mol. Ther.</source><volume>24</volume><year>2016</year><fpage>34</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">26316391</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Daquinag</surname><given-names>A.C.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Amaya-Manzanares</surname><given-names>F.</given-names></name><name><surname>Simmons</surname><given-names>P.J.</given-names></name><name><surname>Kolonin</surname><given-names>M.G.</given-names></name></person-group><article-title>An isoform of decorin is a resistin receptor on the surface of adipose progenitor cells</article-title><source>Cell Stem Cell</source><volume>9</volume><year>2011</year><fpage>74</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">21683670</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Kolonin</surname><given-names>M.G.</given-names></name><name><surname>Saha</surname><given-names>P.K.</given-names></name><name><surname>Chan</surname><given-names>L.</given-names></name><name><surname>Pasqualini</surname><given-names>R.</given-names></name><name><surname>Arap</surname><given-names>W.</given-names></name></person-group><article-title>Reversal of obesity by targeted ablation of adipose tissue</article-title><source>Nat. Med.</source><volume>10</volume><year>2004</year><fpage>625</fpage><lpage>632</lpage><pub-id pub-id-type="pmid">15133506</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Chorev</surname><given-names>M.</given-names></name><name><surname>Goodman</surname><given-names>M.</given-names></name></person-group><article-title>Recent developments in retro peptides and proteins--an ongoing topochemical exploration</article-title><source>Trends Biotechnol.</source><volume>13</volume><year>1995</year><fpage>438</fpage><lpage>445</lpage><pub-id pub-id-type="pmid">7546569</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Daquinag</surname><given-names>A.C.</given-names></name><name><surname>Tseng</surname><given-names>C.</given-names></name><name><surname>Salameh</surname><given-names>A.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Amaya-Manzanares</surname><given-names>F.</given-names></name><name><surname>Dadbin</surname><given-names>A.</given-names></name><name><surname>Florez</surname><given-names>F.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Tong</surname><given-names>Q.</given-names></name><name><surname>Kolonin</surname><given-names>M.G.</given-names></name></person-group><article-title>Depletion of white adipocyte progenitors induces beige adipocyte differentiation and suppresses obesity development</article-title><source>Cell Death Differ.</source><volume>22</volume><year>2015</year><fpage>351</fpage><lpage>363</lpage><pub-id pub-id-type="pmid">25342467</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Ferdous</surname><given-names>Z.</given-names></name><name><surname>Peterson</surname><given-names>S.B.</given-names></name><name><surname>Tseng</surname><given-names>H.</given-names></name><name><surname>Anderson</surname><given-names>D.K.</given-names></name><name><surname>Iozzo</surname><given-names>R.V.</given-names></name><name><surname>Grande-Allen</surname><given-names>K.J.</given-names></name></person-group><article-title>A role for decorin in controlling proliferation, adhesion, and migration of murine embryonic fibroblasts</article-title><source>J.&#x000a0;Biomed. Mater. Res. A</source><volume>93</volume><year>2010</year><fpage>419</fpage><lpage>428</lpage><pub-id pub-id-type="pmid">19569212</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Nie</surname><given-names>J.</given-names></name><name><surname>Chang</surname><given-names>B.</given-names></name><name><surname>Traktuev</surname><given-names>D.O.</given-names></name><name><surname>Sun</surname><given-names>J.</given-names></name><name><surname>March</surname><given-names>K.</given-names></name><name><surname>Chan</surname><given-names>L.</given-names></name><name><surname>Sage</surname><given-names>E.H.</given-names></name><name><surname>Pasqualini</surname><given-names>R.</given-names></name><name><surname>Arap</surname><given-names>W.</given-names></name><name><surname>Kolonin</surname><given-names>M.G.</given-names></name></person-group><article-title>IFATS collection: Combinatorial peptides identify &#x003b1;5&#x003b2;1 integrin as a receptor for the matricellular protein SPARC on adipose stromal cells</article-title><source>Stem Cells</source><volume>26</volume><year>2008</year><fpage>2735</fpage><lpage>2745</lpage><pub-id pub-id-type="pmid">18583538</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Azhdarinia</surname><given-names>A.</given-names></name><name><surname>Daquinag</surname><given-names>A.C.</given-names></name><name><surname>Tseng</surname><given-names>C.</given-names></name><name><surname>Ghosh</surname><given-names>S.C.</given-names></name><name><surname>Ghosh</surname><given-names>P.</given-names></name><name><surname>Amaya-Manzanares</surname><given-names>F.</given-names></name><name><surname>Sevick-Muraca</surname><given-names>E.</given-names></name><name><surname>Kolonin</surname><given-names>M.G.</given-names></name></person-group><article-title>A peptide probe for targeted brown adipose tissue imaging</article-title><source>Nat. Commun.</source><volume>4</volume><year>2013</year><fpage>2472</fpage><lpage>2482</lpage><pub-id pub-id-type="pmid">24045463</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D.</given-names></name><name><surname>Coussens</surname><given-names>L.M.</given-names></name></person-group><article-title>Accessories to the crime: functions of cells recruited to the tumor microenvironment</article-title><source>Cancer Cell</source><volume>21</volume><year>2012</year><fpage>309</fpage><lpage>322</lpage><pub-id pub-id-type="pmid">22439926</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Fukumura</surname><given-names>D.</given-names></name><name><surname>Xavier</surname><given-names>R.</given-names></name><name><surname>Sugiura</surname><given-names>T.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Park</surname><given-names>E.C.</given-names></name><name><surname>Lu</surname><given-names>N.</given-names></name><name><surname>Selig</surname><given-names>M.</given-names></name><name><surname>Nielsen</surname><given-names>G.</given-names></name><name><surname>Taksir</surname><given-names>T.</given-names></name><name><surname>Jain</surname><given-names>R.K.</given-names></name><name><surname>Seed</surname><given-names>B.</given-names></name></person-group><article-title>Tumor induction of VEGF promoter activity in stromal cells</article-title><source>Cell</source><volume>94</volume><year>1998</year><fpage>715</fpage><lpage>725</lpage><pub-id pub-id-type="pmid">9753319</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Bissell</surname><given-names>M.J.</given-names></name><name><surname>Radisky</surname><given-names>D.</given-names></name></person-group><article-title>Putting tumours in context</article-title><source>Nat. Rev. Cancer</source><volume>1</volume><year>2001</year><fpage>46</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">11900251</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Coussens</surname><given-names>L.M.</given-names></name><name><surname>Werb</surname><given-names>Z.</given-names></name></person-group><article-title>Inflammation and cancer</article-title><source>Nature</source><volume>420</volume><year>2002</year><fpage>860</fpage><lpage>867</lpage><pub-id pub-id-type="pmid">12490959</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Kalluri</surname><given-names>R.</given-names></name><name><surname>Zeisberg</surname><given-names>M.</given-names></name></person-group><article-title>Fibroblasts in cancer</article-title><source>Nat. Rev. Cancer</source><volume>6</volume><year>2006</year><fpage>392</fpage><lpage>401</lpage><pub-id pub-id-type="pmid">16572188</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Shojaei</surname><given-names>F.</given-names></name><name><surname>Zhong</surname><given-names>C.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Yu</surname><given-names>L.</given-names></name><name><surname>Ferrara</surname><given-names>N.</given-names></name></person-group><article-title>Role of myeloid cells in tumor angiogenesis and growth</article-title><source>Trends Cell Biol.</source><volume>18</volume><year>2008</year><fpage>372</fpage><lpage>378</lpage><pub-id pub-id-type="pmid">18614368</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Bertolini</surname><given-names>F.</given-names></name><name><surname>Shaked</surname><given-names>Y.</given-names></name><name><surname>Mancuso</surname><given-names>P.</given-names></name><name><surname>Kerbel</surname><given-names>R.S.</given-names></name></person-group><article-title>The multifaceted circulating endothelial cell in cancer: towards marker and target identification</article-title><source>Nat. Rev. Cancer</source><volume>6</volume><year>2006</year><fpage>835</fpage><lpage>845</lpage><pub-id pub-id-type="pmid">17036040</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Wels</surname><given-names>J.</given-names></name><name><surname>Kaplan</surname><given-names>R.N.</given-names></name><name><surname>Rafii</surname><given-names>S.</given-names></name><name><surname>Lyden</surname><given-names>D.</given-names></name></person-group><article-title>Migratory neighbors and distant invaders: tumor-associated niche cells</article-title><source>Genes Dev.</source><volume>22</volume><year>2008</year><fpage>559</fpage><lpage>574</lpage><pub-id pub-id-type="pmid">18316475</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Dvorak</surname><given-names>H.F.</given-names></name></person-group><article-title>Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing</article-title><source>N.&#x000a0;Engl. J. Med.</source><volume>315</volume><year>1986</year><fpage>1650</fpage><lpage>1659</lpage><pub-id pub-id-type="pmid">3537791</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>P.</given-names></name><name><surname>Weaver</surname><given-names>V.M.</given-names></name><name><surname>Werb</surname><given-names>Z.</given-names></name></person-group><article-title>The extracellular matrix: a dynamic niche in cancer progression</article-title><source>J.&#x000a0;Cell Biol.</source><volume>196</volume><year>2012</year><fpage>395</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">22351925</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Sirin</surname><given-names>O.</given-names></name><name><surname>Kolonin</surname><given-names>M.G.</given-names></name></person-group><article-title>Treatment of obesity as a potential complementary approach to cancer therapy</article-title><source>Drug Discov. Today</source><volume>18</volume><year>2013</year><fpage>567</fpage><lpage>573</lpage><pub-id pub-id-type="pmid">22627005</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>Hursting</surname><given-names>S.D.</given-names></name><name><surname>Lavigne</surname><given-names>J.A.</given-names></name><name><surname>Berrigan</surname><given-names>D.</given-names></name><name><surname>Perkins</surname><given-names>S.N.</given-names></name><name><surname>Barrett</surname><given-names>J.C.</given-names></name></person-group><article-title>Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans</article-title><source>Annu. Rev. Med.</source><volume>54</volume><year>2003</year><fpage>131</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">12525670</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>Cowey</surname><given-names>S.</given-names></name><name><surname>Hardy</surname><given-names>R.W.</given-names></name></person-group><article-title>The metabolic syndrome: a high-risk state for cancer?</article-title><source>Am. J. Pathol.</source><volume>169</volume><year>2006</year><fpage>1505</fpage><lpage>1522</lpage><pub-id pub-id-type="pmid">17071576</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J.</given-names></name><name><surname>Morley</surname><given-names>T.S.</given-names></name><name><surname>Kim</surname><given-names>M.</given-names></name><name><surname>Clegg</surname><given-names>D.J.</given-names></name><name><surname>Scherer</surname><given-names>P.E.</given-names></name></person-group><article-title>Obesity and cancer--mechanisms underlying tumour progression and recurrence</article-title><source>Nat. Rev. Endocrinol.</source><volume>10</volume><year>2014</year><fpage>455</fpage><lpage>465</lpage><pub-id pub-id-type="pmid">24935119</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J.</given-names></name><name><surname>Euhus</surname><given-names>D.M.</given-names></name><name><surname>Scherer</surname><given-names>P.E.</given-names></name></person-group><article-title>Paracrine and endocrine effects of adipose tissue on cancer development and progression</article-title><source>Endocr. Rev.</source><volume>32</volume><year>2011</year><fpage>550</fpage><lpage>570</lpage><pub-id pub-id-type="pmid">21642230</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name><surname>Murdoch</surname><given-names>C.</given-names></name><name><surname>Muthana</surname><given-names>M.</given-names></name><name><surname>Coffelt</surname><given-names>S.B.</given-names></name><name><surname>Lewis</surname><given-names>C.E.</given-names></name></person-group><article-title>The role of myeloid cells in the promotion of tumour angiogenesis</article-title><source>Nat. Rev. Cancer</source><volume>8</volume><year>2008</year><fpage>618</fpage><lpage>631</lpage><pub-id pub-id-type="pmid">18633355</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name><surname>Iyengar</surname><given-names>N.M.</given-names></name><name><surname>Brown</surname><given-names>K.A.</given-names></name><name><surname>Zhou</surname><given-names>X.K.</given-names></name><name><surname>Gucalp</surname><given-names>A.</given-names></name><name><surname>Subbaramaiah</surname><given-names>K.</given-names></name><name><surname>Giri</surname><given-names>D.D.</given-names></name><name><surname>Zahid</surname><given-names>H.</given-names></name><name><surname>Bhardwaj</surname><given-names>P.</given-names></name><name><surname>Wendel</surname><given-names>N.K.</given-names></name><name><surname>Falcone</surname><given-names>D.J.</given-names></name></person-group><article-title>Metabolic obesity, adipose inflammation and elevated breast aromatase in women with normal body mass index</article-title><source>Cancer Prev. Res. (Phila.)</source><volume>10</volume><year>2017</year><fpage>235</fpage><lpage>243</lpage><pub-id pub-id-type="pmid">28270386</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name><surname>Mullooly</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>H.P.</given-names></name><name><surname>Falk</surname><given-names>R.T.</given-names></name><name><surname>Nyante</surname><given-names>S.J.</given-names></name><name><surname>Cora</surname><given-names>R.</given-names></name><name><surname>Pfeiffer</surname><given-names>R.M.</given-names></name><name><surname>Radisky</surname><given-names>D.C.</given-names></name><name><surname>Visscher</surname><given-names>D.W.</given-names></name><name><surname>Hartmann</surname><given-names>L.C.</given-names></name><name><surname>Carter</surname><given-names>J.M.</given-names></name></person-group><article-title>Relationship between crown-like structures and sex-steroid hormones in breast adipose tissue and serum among postmenopausal breast cancer patients</article-title><source>Breast Cancer Res.</source><volume>19</volume><year>2017</year><fpage>8</fpage><pub-id pub-id-type="pmid">28103902</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name><surname>Gubbiotti</surname><given-names>M.A.</given-names></name><name><surname>Vallet</surname><given-names>S.D.</given-names></name><name><surname>Ricard-Blum</surname><given-names>S.</given-names></name><name><surname>Iozzo</surname><given-names>R.V.</given-names></name></person-group><article-title>Decorin interacting network: a comprehensive analysis of decorin-binding partners and their versatile functions</article-title><source>Matrix Biol.</source><volume>55</volume><year>2016</year><fpage>7</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">27693454</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name><surname>Baghy</surname><given-names>K.</given-names></name><name><surname>Horv&#x000e1;th</surname><given-names>Z.</given-names></name><name><surname>Reg&#x00151;s</surname><given-names>E.</given-names></name><name><surname>Kiss</surname><given-names>K.</given-names></name><name><surname>Schaff</surname><given-names>Z.</given-names></name><name><surname>Iozzo</surname><given-names>R.V.</given-names></name><name><surname>Kovalszky</surname><given-names>I.</given-names></name></person-group><article-title>Decorin interferes with platelet-derived growth factor receptor signaling in experimental hepatocarcinogenesis</article-title><source>FEBS J.</source><volume>280</volume><year>2013</year><fpage>2150</fpage><lpage>2164</lpage><pub-id pub-id-type="pmid">23448253</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name><surname>Cong</surname><given-names>L.</given-names></name><name><surname>Ran</surname><given-names>F.A.</given-names></name><name><surname>Cox</surname><given-names>D.</given-names></name><name><surname>Lin</surname><given-names>S.</given-names></name><name><surname>Barretto</surname><given-names>R.</given-names></name><name><surname>Habib</surname><given-names>N.</given-names></name><name><surname>Hsu</surname><given-names>P.D.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Jiang</surname><given-names>W.</given-names></name><name><surname>Marraffini</surname><given-names>L.A.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name></person-group><article-title>Multiplex genome engineering using CRISPR/Cas systems</article-title><source>Science</source><volume>339</volume><year>2013</year><fpage>819</fpage><lpage>823</lpage><pub-id pub-id-type="pmid">23287718</pub-id></element-citation></ref></ref-list><sec id="app2" sec-type="supplementary-material"><title>Supplemental Information</title><p><supplementary-material content-type="local-data" id="mmc1"><caption><title>Document S1. Figures S1&#x02013;S5</title></caption><media xlink:href="mmc1.pdf"/></supplementary-material><supplementary-material content-type="local-data" id="mmc2"><caption><title>Document S2. Article plus Supplemental Information</title></caption><media xlink:href="mmc2.pdf"/></supplementary-material></p></sec><ack id="ack0010"><title>Acknowledgments</title><p>We thank Zhanguo Gao and Angielyn Rivera for technical assistance. We thank Renato Iozzo and Jane Grande-Allen for sharing DCN-null MEFs. We thank Askar Kuchumov, Eugene Shevchenko, and Andrew Makarovskiy for many helpful discussions. This work was supported in part by <funding-source id="gs1">CTSA</funding-source> award UL1 TR000371.</p></ack><fn-group><fn id="app1" fn-type="supplementary-material"><p>Supplemental Information includes five figures and can be found with this article online at <ext-link ext-link-type="doi" xlink:href="10.1016/j.omto.2017.05.003" id="intref0010">http://dx.doi.org/10.1016/j.omto.2017.05.003</ext-link>.</p></fn></fn-group></back></article>